Back to mobile site

TD Cowen on Intellia Therapeutics (NTLA): 'We see the Ph. III results as solid'

April 27, 2026 10:48 AM EDT Send to a Friend
TD Cowen analyst Joseph Thome reiterated a Buy rating on Intellia Therapeutics ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login